Jung-Min  Lee, M.D.
Jung-Min Lee, M.D.
Assistant Clinical Investigator

Center for Cancer Research
National Cancer Institute

Building 10, Room 13N218
Bethesda, MD 20892
301-443-7735

Dr. Lee’s research is focused on the early clinical drug development and translational studies of targeted agents in BRCA mutation-associated breast or ovarian cancer, high-grade epithelial ovarian cancer, and triple negative breast cancer, as these diseases share the similar molecular abnormalities. Her clinical and translational research interests include examining the hypothesis of clinical synergy of the combination of targeting key proteins in the DNA damage repair pathways, cell cycle, tumor microenvironment, and immune check points in clinical trials, incorporating collected patient tissue and blood samples. She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents.

Areas of Expertise
1) ovarian cancer, 2) BRCA mutation, 3) triple negative breast cancer, 4) early clinical trials, 5) biomarkers

Dr. Lee's research interests include the early clinical drug development and translational studies of targeted agents in triple negative breast cancer (TNBC) and ovarian cancer, as these diseases share the similar molecular abnormalities, such as TP53 and Rb mutations. Her translational and clinical research interests include examining the hypothesis of clinical synergy of the combination of targeting key proteins in the DNA damage repair pathways, cell cycle, tumor microenvironment, and apoptotic pathways in clinical trials, incorporating collected patient tissue and blood samples. She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents. Dr. Lee's ASCO Young Investigator Award project is to test hypothesis of underlying sequence specificity of DNA damage by a PARP inhibitor and carboplatin, both at the preclinical and clinical levels. In addition, her New York Ovarian Cancer Research Award project is to develop a flow cytometric method to examine potential biomarkers of response to PARP inhibitor therapy in high-grade ovarian cancer. Dr. Lee's group is also interested in pursuing other potential biomarkers of response to targeted agents for cell cycle, apoptotic pathways, and targeted pathways pertinent to TNBC and high-grade serous ovarian cancer. She looks forward to advancing the preclinical biomarker and activity data into new clinical studies for women's cancers.

Scientific Focus Areas:
Cancer Biology, Cell Biology, Clinical Research, Molecular Biology and Biochemistry
Selected Recent Publications
  1. Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC
    J. National Cancer Inst. 106(6): dju089, 2014. [ Journal Article ]
  2. Lee JM, Ledermann JA, Kohn EC.
    Ann. Oncol. 25: 32-40, 2014. [ Journal Article ]
  3. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA
    Lancet Oncology. 15(11): 1207-1214, 2014. [ Journal Article ]
  4. O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
    Front Oncol. 4: 42, 2014. [ Journal Article ]
  5. Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
    Br. J. Cancer. 109(4): 1072-1078, 2013. [ Journal Article ]

Dr. Lee is a graduate of Yonsei University, Wonju College of Medicine in South Korea. She completed residency training in internal medicine at the Albert Einstein Medical College, followed by a clinical research fellowship on breast cancer functional imaging at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Lee came to the NCI for medical oncology training in the Medical Oncology Branch (MOB). Subsequently, she joined the Molecular Signaling Section/Women's Cancers Clinic, MOB, to investigate potential biomarkers and develop rational combinations of targeted therapies for rare subsets of women's cancers. Dr. Lee maintains her clinical focus in the development of early clinical trials for ovarian cancer and rare subsets of women's cancers, such as BRCA1/2mut carriers with ovarian and/or breast cancers, or women with triple negative breast cancer (TNBC). Dr. Lee is a participating member in the Gynecologic Oncology Group, American Association for Cancer Research, American Society for Clinical Oncology, and the Breast and Gynecologic Malignancies Faculty of the CCR. She was awarded the 2011 Jane C. Wright M.D. Young Investigator Award from the American Society of Clinical Oncology and the 2012 New York Ovarian Cancer Research Award from the Foundation for Women's Cancers.

Name Position
Victoria Chiou M.D. Clinical Fellow
Irene B. Ekwede R.N. Research Nurse
Nicolas M. Gordon B.S. Postbaccalaureate Fellow
Nicole D. Houston R.N. Clinical Research Nurse
Alyssa Stacy B.S. Postbaccalaureate Fellow
Takuhei Yokoyama M.D., Ph.D. Postdoctoral Fellow (CRTA)
Minshu Yu M.D., Ph.D. Research Biologist

Summary

Dr. Lee’s research is focused on the early clinical drug development and translational studies of targeted agents in BRCA mutation-associated breast or ovarian cancer, high-grade epithelial ovarian cancer, and triple negative breast cancer, as these diseases share the similar molecular abnormalities. Her clinical and translational research interests include examining the hypothesis of clinical synergy of the combination of targeting key proteins in the DNA damage repair pathways, cell cycle, tumor microenvironment, and immune check points in clinical trials, incorporating collected patient tissue and blood samples. She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents.

Areas of Expertise
1) ovarian cancer, 2) BRCA mutation, 3) triple negative breast cancer, 4) early clinical trials, 5) biomarkers

Clinical Trials

Research

Dr. Lee's research interests include the early clinical drug development and translational studies of targeted agents in triple negative breast cancer (TNBC) and ovarian cancer, as these diseases share the similar molecular abnormalities, such as TP53 and Rb mutations. Her translational and clinical research interests include examining the hypothesis of clinical synergy of the combination of targeting key proteins in the DNA damage repair pathways, cell cycle, tumor microenvironment, and apoptotic pathways in clinical trials, incorporating collected patient tissue and blood samples. She is the principal investigator of ongoing phase 1 and 2 studies, with a PARP inhibitor (olaparib) in combination with carboplatin or cediranib, and other biologic agents. Dr. Lee's ASCO Young Investigator Award project is to test hypothesis of underlying sequence specificity of DNA damage by a PARP inhibitor and carboplatin, both at the preclinical and clinical levels. In addition, her New York Ovarian Cancer Research Award project is to develop a flow cytometric method to examine potential biomarkers of response to PARP inhibitor therapy in high-grade ovarian cancer. Dr. Lee's group is also interested in pursuing other potential biomarkers of response to targeted agents for cell cycle, apoptotic pathways, and targeted pathways pertinent to TNBC and high-grade serous ovarian cancer. She looks forward to advancing the preclinical biomarker and activity data into new clinical studies for women's cancers.

Scientific Focus Areas:
Cancer Biology, Cell Biology, Clinical Research, Molecular Biology and Biochemistry

Publications

Selected Recent Publications
  1. Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC
    J. National Cancer Inst. 106(6): dju089, 2014. [ Journal Article ]
  2. Lee JM, Ledermann JA, Kohn EC.
    Ann. Oncol. 25: 32-40, 2014. [ Journal Article ]
  3. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA
    Lancet Oncology. 15(11): 1207-1214, 2014. [ Journal Article ]
  4. O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
    Front Oncol. 4: 42, 2014. [ Journal Article ]
  5. Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
    Br. J. Cancer. 109(4): 1072-1078, 2013. [ Journal Article ]

Biography

Dr. Lee is a graduate of Yonsei University, Wonju College of Medicine in South Korea. She completed residency training in internal medicine at the Albert Einstein Medical College, followed by a clinical research fellowship on breast cancer functional imaging at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Lee came to the NCI for medical oncology training in the Medical Oncology Branch (MOB). Subsequently, she joined the Molecular Signaling Section/Women's Cancers Clinic, MOB, to investigate potential biomarkers and develop rational combinations of targeted therapies for rare subsets of women's cancers. Dr. Lee maintains her clinical focus in the development of early clinical trials for ovarian cancer and rare subsets of women's cancers, such as BRCA1/2mut carriers with ovarian and/or breast cancers, or women with triple negative breast cancer (TNBC). Dr. Lee is a participating member in the Gynecologic Oncology Group, American Association for Cancer Research, American Society for Clinical Oncology, and the Breast and Gynecologic Malignancies Faculty of the CCR. She was awarded the 2011 Jane C. Wright M.D. Young Investigator Award from the American Society of Clinical Oncology and the 2012 New York Ovarian Cancer Research Award from the Foundation for Women's Cancers.

Team

Name Position
Victoria Chiou M.D. Clinical Fellow
Irene B. Ekwede R.N. Research Nurse
Nicolas M. Gordon B.S. Postbaccalaureate Fellow
Nicole D. Houston R.N. Clinical Research Nurse
Alyssa Stacy B.S. Postbaccalaureate Fellow
Takuhei Yokoyama M.D., Ph.D. Postdoctoral Fellow (CRTA)
Minshu Yu M.D., Ph.D. Research Biologist